Legal peptide access is coming
When the FDA finalizes the 2026 reclassification, 14 peptides — including BPC-157, TB-500, and Thymosin Alpha-1 — will return to legal compounding status. Valitide is building a telehealth platform to connect you with licensed providers and pharmacies for prescription access.
Join the waitlist to be notified when we launch. No spam — only real regulatory updates and access announcements.
What you'll get access to
- ✓Prescription peptides from licensed compounding pharmacies
- ✓Virtual consultations with licensed telehealth providers
- ✓Pharmaceutical-grade compounds with full COA documentation
- ✓Shipped directly to your door
Peptides expected to become available
Pending formal FDA rulemaking. These peptides are currently Category 2 and cannot yet be legally compounded. Track the reclassification timeline →
Valitide is not a healthcare provider. Telehealth consultations will be provided by independent licensed providers. Medications will be dispensed by licensed compounding pharmacies. All peptide access requires a valid prescription.